Validation of PDXK as a novel GDM diabetes gene
In eukaryotes Pyridoxal kinase produces the active form of vitamin B6 named Pyridoxal 5¿-phosphate (PLP) which is implicated in numerous metabolic reactions. In Drosophila mutations in dPdxk gene cause chromosome aberrations (CABs), increase glucose content in larval hemolymph and cause insulin resistance. Studies suggesting that vitamin B6 supplementation influences glucose tolerance in pregnant women prompted us to investigate PDXK in women with gestational diabetes (GD). We performed a screening by sequencing PDXK in 400 GDM women and identified a novel PDXK variant (A243G) in two women. By considering the wide evolutionarily conservation of molecules and pathways involved in glucose homeostasis maintenance and the finding that human PDXK gene inserted in dPdxk1 flies is able to rescue hyperglycemia, we reasoned that Drosophila is a robust model to validate this variant. Thus, the purpose of this project is to express the A243G PDXK variant in a dPdxk1 mutant background and to investigate if it is able to rescue hyperglycemia and insulin resistance. Diabetes causes oxidative stress resulting in the production of oxygen reactive species (ROS) which in turn cause DNA and chromosome damage. We previously demonstrated that in dPdxk1 mutants hyperglycemia induces the accumulation of Advanced Glycation End product (AGEs) which in turn elicit the formation of CABs. Thus, in the present project we will also verify if the expression of A243G PDXK variant impacts on CABs and AGE accumulation. We will also assay whether supplementation with PLP precursors (PL, PM and PN), influence the rescue of hyperglycemia and CABs in A243G expressing cells in order to obtain indications on the putative biochemical defect of the mutant protein that will be subsequently investigate. The validation of A343G in Drosophila will provide us a first indication of the association between PDXK gene and diabetes that will be in the future deeply addressed in human cells.